Solara Active Pharma Sciences Limited (BOM:541540)
India · Delayed Price · Currency is INR | Market Cap | 26.59B |
| Revenue (ttm) | 12.06B |
| Net Income (ttm) | 64.10M |
| Shares Out | n/a |
| EPS (ttm) | 1.95 |
| PE Ratio | 414.82 |
| Forward PE | 16.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,960 |
| Average Volume | 11,889 |
| Open | 539.05 |
| Previous Close | 550.35 |
| Day's Range | 539.05 - 554.20 |
| 52-Week Range | 441.10 - 812.95 |
| Beta | n/a |
| RSI | 48.04 |
| Earnings Date | Oct 24, 2025 |
About BOM:541540
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antif... [Read more]
Financial Performance
Financial StatementsNews
Solara Active Pharma’s Mangalore facility clears US FDA inspection with VAI classification
Solara Active Pharma Sciences Limited has received a positive regulatory update for its Mangalore manufacturing site, strengthening its position as...
Solara Active Pharma Sciences Ltd (BOM:541540) Q2 2026 Earnings Call Highlights: Navigating ...
Solara Active Pharma Sciences Ltd (BOM:541540) Q2 2026 Earnings Call Highlights: Navigating Challenges with Strategic Debt Reduction and Market Expansion
Q2 2026 Solara Active Pharma Sciences Ltd Earnings Call Transcript
Q2 2026 Solara Active Pharma Sciences Ltd Earnings Call Transcript
Solara Active Pharma shares slump nearly 9% today after reporting Q2 net loss
Shares of Solara Active Pharma Sciences Ltd plunged 8.77% to Rs 563.00 in early trade on Thursday after the company...
Solara Active Pharma shares rise 4% after Ambernath facility clears USFDA inspection with zero observations
Shares of Solara Active Pharma Sciences Ltd surged nearly 4% to ₹523.35 on Monday after the company announced that its Ambernath manufacturing facility in Maharashtra has successfully cleared a US Foo...
Solara Active Pharma shares down 5% as Managing Director Poorvank Purohit resigns
Shares of Solara Active Pharma Sciences Ltd declined 5% in early trade on February 24, following the announcement of Managing Director (MD) and CEO Poorvank Purohit’s resignation. The stock dropped to...
Solara Active Pharma Sciences announces demerger of CRAMS and Polymers business
Solara Active Pharma Sciences has announced the demerger of its CRAMS (Contract Research and Manufacturing Services) and Polymers business from the Generic API business (Catalog API). The move is expe...
Solara Active Pharma Sciences Q3 FY25 Results: Revenue up 41.6% YoY to Rs 300.31 crore
Solara Active Pharma Sciences Limited announced its financial results for the quarter ended December 31, 2024, showing a consistent performance across key financial metrics. Key Financial Highlights: ...